Trial Profile
Phase II Study of Crizotinib in Japanese Patients with Advanced MET exon14 skipping mutation-positive or MET high gene copy number-positive non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Co-MET
- 08 Oct 2021 Status changed from active, no longer recruiting to completed.
- 09 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.